Pangaea Oncology –located at the Dexeus University Hospital and associated company of PCB – has been the first laboratory to be accredited in Spain for the determination of oncological biomarkers in blood (liquid biopsy) by the norm UNE-EN ISO 15189. This laboratory has great experience in the field of oncology, and was the first to be accredite in 2009 for the analysis in tissue of mutations in genes related to tumor processes, specifically in lung cancer. The result of these analyzes allows to predict the response to certain drugs and to apply personalized medicine to patients.
Pangaea Oncology provides Molecular Diagnostics and R+D services in the field of personalized cancer treatment. Founded in 2007, the company has grown rapidly to become a reference laboratory in the field of non-invasive diagnostic assays using alternative biosources such as serum, plasma and platelets from blood samples (liquid biopsy).
In certain cancers such as lung cancer, lack of sufficient biopsied tumor tissue can make it difficult or impossible to perform vital diagnostic tests. These blood-based assays not only overcome this challenge, but also offer the possibility of long-term serial monitoring of response in real time and early detection of therapy resistance.
Photo: Pangaea Oncology
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del...
Investigadores del Cima Universidad de Navarra constatan que la combin...
